ADVFN - Advanced Financial Network.
HOME» NASDAQ » A » AMGN Stock Price » AMGN Stock News

Amgen Inc. Share News

 Amgen Inc. (mm) Stock Price
AMGN Stock Price
 Amgen Inc. (mm) Stock Chart
AMGN Stock Chart
 Amgen Inc. (mm) Stock News
AMGN Stock News
 Amgen Inc. (mm) Company Information
AMGN Company Information
 Amgen Inc. (mm) Stock Trades
AMGN Stock Trades

MARKET SNAPSHOT: U.S. Stocks Rise With Odds Of Intervention

By Kate Gibson, MarketWatch NEW YORK (MarketWatch) -- U.S. stocks rallied Friday to reclaim weekly gains as investors anticipated central-bank moves in Europe as well as by the U.S. Federal Reserve. The market is "bid up on prospects of monetary intervention," said Mark Luschini, chief investment strategist at Janney Montgomery Scott. The Dow Jones Industrial Average (DJI) rose 107.16 points, or 0.8%, to 12,995.09, with Merck & Co. Inc. (MRK) leading gains that included all but two of its 30 components. Merck shares rallied 3.1% after the pharmaceutical company's earnings topped forecasts. The S&P 500 index (SPX) added 14.93 points, or 1.1%, to 1,374.95, with health-care the best performing and energy the sole laggard among its 10 sectors. Amgen Inc. (AMGN) gained 4% after the biotechnology company hiked its 2012 outlook and reported second-quarter profit that exceeded analysts' estimates. The Nasdaq Composite (RIXF) gained 34.52 points, or 1.2%, to 2,927.77. Facebook Inc. (FB) shares slid nearly 13% after the social-networking site offered little reassurance to investors concerned about its lofty valuation. For every stock declining, more than four gained on the New York Stock Exchange, where 261 million shares were exchanged as of 11:40 a.m. Eastern. Global equities gained after German Chancellor Angela Merkel and French President Francois Hollande said they are committed to keeping the euro area together. French newspaper Le Monde reported the European Central Bank was readying to purchase debt. The major stock indexes held gains after a gauge of consumer sentiment came in just above expectations, as did a separate report on U.S. economic growth in the second quarter. . Subscribe to WSJ: http://online.wsj.com?mod=djnwires

Stock News for Amgen Inc. (AMGN)
DateTimeHeadline
02/14/201718:12:25Automatic Shelf Registration Statement of Securities of Well-known...
02/14/201717:07:24Annual Report (10-k)
02/14/201710:47:10Statement of Ownership (sc 13g)
02/14/201709:00:00Amgen Submits Supplemental Biologics License Application For...
02/13/201716:41:37Amended Statement of Ownership (sc 13g/a)
02/09/201712:01:10Amended Statement of Ownership (sc 13g/a)
02/08/201719:32:00Appeals Court Allows Sanofi, Regeneron to Continue Selling Cholesterol...
02/07/201718:13:00FDA Approves Amgen's Parsabiv™ (Etelcalcetide), First New Treatment I...
02/03/201717:08:12Current Report Filing (8-k)
02/03/201716:04:00Amgen Announces Appointment of Charles M. Holley Jr. to Board...
02/03/201712:59:00Good News for Amgen Is God News for Biotech
02/02/201719:20:00Correction to Amgen Repatha Story
02/02/201718:54:30Statement of Changes in Beneficial Ownership (4)
02/02/201718:48:51Statement of Changes in Beneficial Ownership (4)
02/02/201717:07:00Amgen Sees Positive Results in Repatha Study -- 2nd Update
02/02/201717:02:00Amgen Sees Positive Results in Repatha Study
02/02/201716:56:39Current Report Filing (8-k)
02/02/201716:36:00Amgen's Profit Rises on Improved Margins, Steady Top-line Growth
02/02/201716:20:00Amgen Reports Fourth Quarter And Full Year 2016 Financial Results
02/02/201716:00:00Amgen Announces Repatha® (Evolocumab) Significantly Reduced...

Amgen Inc. and other NASDAQ stock quotes are delayed by at least 20 minutes.
All other stock price and quote data is delayed by at least 15 minutes unless otherwise stated. By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Contact Us | Copyright 1999-2016 ADVFN PLC. | Privacy Policy | Investment Warning | Data accreditations | Investor Relations

ADVFNADVFN ItalyADVFN GermanyADVFN FranceADVFN BrazilADVFN JapanADVFN UKADVFN US